
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72830
10.1038/s41598-024-72830-0
Article
Establishment and characterization of a novel human gallbladder cancer cell line, GBC-X1
Chai Changpeng 12
Tang Huan 2
Miao Xin 34
Chen Tingting 2
Su Yuanhui 2
Li Lu 1
Miao Long 12
Zhang Bo 1
Wang Zhengfeng 12
Luo Wei 1
Zhang Hui 25
Xu Hao amoyxu@126.com

146
Zhou Wence zhouwc129@163.com

25
1 https://ror.org/05d2xpa49 grid.412643.6 The Fourth Department of General Surgery, The First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000 Gansu China
2 https://ror.org/01mkqqe32 grid.32566.34 0000 0000 8571 0482 The Second Clinical Medical College, Lanzhou University, Lanzhou, 730000 China
3 grid.454892.6 0000 0001 0018 8988 State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, 730000 China
4 https://ror.org/04epb4p87 grid.268505.c 0000 0000 8744 8924 First School of Clinical Medicine, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006 China
5 https://ror.org/02erhaz63 grid.411294.b 0000 0004 1798 9345 Department of General Surgery, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730000 China
6 https://ror.org/01mkqqe32 grid.32566.34 0000 0000 8571 0482 The First Clinical Medical College, Lanzhou University, Lanzhou, 730000 China
13 9 2024
13 9 2024
2024
14 2143913 4 2024
11 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
In this study, we successfully established a novel gallbladder cancer cell line, designated as GBC-X1, derived from a primary tumor of a gallbladder cancer patient. By comprehensively analyzing the cell line’s phenotype, molecular characteristics, biomarkers, and histological characteristics, we confirmed that GBC-X1 serves as a valuable model for investigating the pathogenesis of gallbladder cancer and developing therapeutic agents. GBC-X1 has been continuously cultured for one year, with over 60 stable passages. Morphologically, GBC-X1 exhibits typical features of epithelial tumors. The population doubling time of GBC-X1 is 32 h. STR analysis validated a high consistency between GBC-X1 and the patient’s primary tumor. Karyotype analysis revealed an abnormal hypertetraploid karyotype for GBC-X1, characterized by representative karyotypes of 98, XXXX del (4) p (12) del (5) p (21) der (10). Under suspension culture conditions, GBC-X1 efficiently forms tumor balls, while subcutaneous inoculation of GBC-X1 cells into NXG mice leads to xenograft formation with a rate of 80%. Drug sensitivity testing demonstrated that GBC-X1 is resistant to oxaliplatin and sensitive to 5-FU, gemcitabine, and paclitaxel. Immunohistochemistry revealed positive expression of CK7, CK19, E-cadherin, MMP-2, CD44, SOX2, and TP53 in GBC-X1 cells, weak positive expression of Vimentin, and a Ki67 positive rate of 35%. Our research highlights GBC-X1 as a novel gallbladder cancer cell line and emphasizes its potential as an effective experimental model for investigating the pathogenesis of gallbladder cancer and drug development.

Keywords

Gallbladder cancer
Cell line
Establishment
Drug resistance
Subject terms

Cancer models
Cancer stem cells
Cancer therapy
Biliary tract cancer
Cancer
Gastrointestinal diseases
Gastrointestinal models
Gansu Provincial Science and Technology Plan23JRRA0929 22JR5RA901 22JR11RA022 Lanzhou Science and Technology Plan Project2022-3-45 2023-2-38 National Natural Science Foundation of China82360510 82260555 Intra-Hospital Fund of the First Hospital of Lanzhou Universityldyyyn2022-12 Natural Science Foundation of Gansu Province23JRRA1601 Chengguan District Science and Technology Plan2023SHFZ0018 issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Gallbladder cancer commonly originates from the mucosal epithelium of the gallbladder and represents the most prevalent and highly prognostically unfavorable malignant tumor in the biliary system1,2. In 2020, there were approximately 19.3 million newly diagnosed cancer cases worldwide, resulting in nearly 10 million cancer-related deaths. Among these cases, gallbladder cancer accounted for 0.6% of newly diagnosed cancer patients and 0.9% of cancer-related deaths3. Gallbladder cancer has obvious geographical distribution characteristics, among which Bolivia in South America, Chile, northern India, Eastern Europe, and some Southeast Asian countries have higher incidence rate; The incidence rate is the lowest in European origin regions such as the United States, Australia, Canada, the United Kingdom and New Zealand4,5. Gallbladder cancer is one of the few tumors showing global gender differences. The incidence rate of women is three to six times higher than that of men6. The overall incidence rate in China is about 3.82/100,000, of which the incidence rate in Shanghai can reach 7.8/100,000. In recent years, the incidence rate in China has been rising, causing more and more attention7,8. Radical surgery remains the sole approach to achieving long-term survival for gallbladder cancer patients. However, this disease exhibits covert initial onset, marked malignancy, pronounced invasiveness, and a propensity for metastasis and dissemination. Early diagnosis is only possible for a meager 10–20% of patients9,10, with the majority being diagnosed at advanced stages, thus missing the opportunity for surgical intervention. The 5-year survival rate for patients with advanced gallbladder cancer ranges from a mere 5–15% 4,11.

In 1980, Koyama established the world’s first gallbladder cancer cell line, G-415. Since then, researchers from Japan and Korea have subsequently established multiple gallbladder cancer cell lines11,12. These cell lines closely mirror the characteristics of primary tumors, rendering the insights derived from their study more representative of the actual in vivo conditions13. Given the variation in tumor etiology, tumor heterogeneity, and genetic diversity influenced by race14–17, the establishment of a diverse range of gallbladder cancer cell lines assumes significant importance in facilitating basic research and drug development pertaining to this disease.

In this study, we successfully established a stable gallbladder cancer cell line, designated as GBC-X1, using surgically resected tumor tissue obtained from a gallbladder cancer patient. GBC-X1 represents a valuable experimental model for gallbladder cancer research.

Materials and methods

Source of human tissue

The tumor tissue was obtained from a 72-year-old female patient who underwent radical cholecystectomy at Lanzhou University Second Hospital on May 9, 2022. The patient presented with a gallbladder tumor, had no history of smoking and drinking, and had a past medical history of hepatitis B infection. Preoperative laboratory tests showed CEA levels of 9.9 ng/ml (reference range: 0-5.2 ng/ml), AFP levels of 1.2 U/ml (reference range: 0-5.8 U/ml), and CA19-9 levels of 49.6 U/ml (reference range: 0-35U/ml) (Table 1). Preoperative CT findings confirmed the presence of gallbladder cancer (Fig. 1A-B).Table 1 Clinical data of the patient

Cell line	Patient age/ethicity	Gender	Current
Status
(days)	Histopathology/ differentiation	Tumor size(cm)	Prior
therapy	Culture
date	Serum	
								AFP
IU/ml
(0-5.8)	CEA
ng/ml
(0-5.2)	CA19-9
U/ml
(0-35)	
GBC-X1	72/Asian	Female	NA	Moderately-poorly	3×2	None	2022-5-9	1.2	9.9	49.6	

Fig. 1 Clinical and pathological profle of GBC-X1.A and B: The patient’s preoperative CT scan results showed a huge mass at the bottom of the gallbladder (arrow). C: On the gross view of the postoperative specimen, a cauliflower-like mass can be seen in the gallbladder (arrow). D: Morphology of GBC-X1 cells under light microscopy ( scale bar = 50 μm). E: The patient’s primary tumor showed moderately to poorly differentiated. The tumor cells displayed irregular arrangements in glandular, tubular, cord-like, and nest-like patterns (scale bar = 50 μm). F: GBC-X1 cells were varying shapes, primarily short fusiform, characterized by enlarged nuclei, prominent nucleoli, limited cytoplasm, and the presence of multinucleated and megakaryocytic cells (scale bar = 50 μm).

A 4 × 4 cm neoplasm was observed in the gallbladder (Fig. 1C). Tissues were collected from the primary lesion for primary culture and subculture.

This study was approved by the Medical Ethics Committee of Lanzhou University Second Hospital (2023 A-381), and the patient provided an informed consent form.

Drugs

Gemcitabine was obtained from Jiangsu Haosen Pharmaceutical Group Co., Ltd., oxaliplatin from Jiangsu Hengrui Pharmaceutical Co., Ltd., 5-FU from Tianjin Jinyao Pharmaceutical Co., Ltd., and paclitaxel from Jiangsu Aosaikang Pharmaceutical Co., Ltd.

NXG mice

Two batches of NXG mice (2 and 3 mice), aged 5–6 weeks, weighing 11 g and 17 g, were used as experimental animals. The mice were purchased from Changzhou Cavens Experimental Animal Co., Ltd. and housed in the SPF level laboratory of the Animal Experimental Center at Lanzhou University. The animal protocol was designed to minimize pain or discomfort to the animals. The animals were acclimatized to laboratory conditions (23℃, 12 h/12 h light/dark, 50% humidity, ad libitum access to food and water) for 2 wk prior to experimentation. The animals were fed an autoclaved rodent diet ad libitum. The mice bedding, feed and water were replaced every 2 days. All procedures followed the institutional and national guidelines for the care and use of laboratory animals. Animal health and behavior were monitored every day for 4 weeks. When the maximum diameter of the Xenograft tumor approaches 1.5 cm or when the Xenograft tumor grows for one month, the mice were killed. All animals were euthanized by barbiturate overdose (intravenous injection, 150 mg/kg pentobarbital sodium) for tissue collection. Death was confirmed by loss of heartbeat, breathing and pupil response.

Animal experiments were reviewed and approved by the Medical Animal Experiment Ethics Committee of Lanzhou University Second Hospital (D2023-318). The all experiments were conducted in accordance with the ARRIVE guidelines and the Guidelines for the Care and Use of Laboratory Animals of China.

The following methods were similar or identical to those employed in previous studies18.

Primary culture, cell purification, and cell line establishment

The tumor tissue was rinsed with sterile PBS (catalog no.10010023, Gibco, USA) 3–5 times, minced as finely as possible, and then digested with type II collagenase (catalog no.17101015, Gibco, USA) and dispase (catalog no.17105041, Invitrogen, USA) in a shaking incubator at 37 ℃. Once the tissue blocks were partially digested, the supernatant was collected, filtered through a 100-mesh filter, and centrifuged at 300 g for 3 min. The supernatant was discarded, and the cell pellet was resuspended in PBS, followed by centrifugation at 300 g for 3 min. The entire culture medium (RPMI-1640(catalog no.c3010-0500, BI, Israel) + 10% FBS (catalog no.04-002-1 A, BI, Israel) + 1% penicillin-streptomycin (catalog no.03-031-1B, BI, Israel)) was added to the pellet and thoroughly mixed. The cell suspension was then evenly seeded into a six-well plate (catalog no.703001, NEST, China). The culture medium was changed after 48 h. Mechanical scraping was performed to remove any fibroblast contamination during the primary culture process. When the cells reached 80% confluency, they were trypsinized and passaged. The cell growth status was regularly monitored under an optical microscope. Starting from the third generation, cells were passaged at a 1:2 ratio and cryopreserved using a serum-free rapid cell cryopreservation solution (catalog no.MF699-01, Mei5 Biotechnology Co.,Ltd, China).

Cell growth curve

GBC-X1 cells (P25) in the logarithmic growth phase were trypsinized and adjusted to a cell density of 6 × 104/ml. Then 0.1 ml of the cell suspension was inoculated into each well of a 96-well plate. CCK-8 (catalog no.ck04, Dojindo, Japan) reagent was added simultaneously and incubated for 2 h for four consecutive days. The UV absorbance value at a wavelength of 450 nm was measured using an enzyme-linked immunosorbent assay reader, and a standard curve was plotted. Population doubling time were computed with several time points, using the “cell calculator++”tool [V. Roth MD, Doubling Time Calculator (2006), https://doubling-time.com/compute_more.php].

Short tandem repeat analysis

GBC-X1 cells (P15) in the logarithmic growth phase were collected after trypsin digestion (catalog no.03-050-1BCS, BI, Israel). STR analysis was performed by Suzhou Genetic Testing Biotechnology Company to establish the correlation between the cells and the primary tumor tissue.

Karyotype analysis

GBC-X1 cells (P42) in the logarithmic growth phase were treated with 0.25 µg/mL colchicine for 6 h at 37 ℃. Metaphase cells were collected, and fixed with methanol acetic acid (3:1). After trypsin digestion, the specimens were stained with Giemsa staining solution. The specimens were analyzed under a microscope. Select well dispersed and moderately stained mitotic phases for karyotype analysis.

Tumor sphere formation assay

Logarithmically growing cells were collected, and 1.5 × 105 cells were inoculated per well into a 6-well plate (Ultra-Low attachment Plate)(catalog no.3471, Corning, USA) after trypsin digestion. The cells were cultured in serum-free RPMI-1640 medium, and tumor sphere formation was assessed on days 7, 10, and 14 after seeding.

Scanning electron microscope

Cells from 30 passages in the logarithmic growth phase were used for the experiments. Cell slides were washed with physiological saline and quickly immersed in 4% glutaraldehyde (product of SPI-CHEM, USA) fixative solution. After rinsing three times with phosphate buffer, the cells were dehydrated using a stepwise gradient of tert-butanol (50%, 70%, 80%, 90%, 100%) for 5 min each. The dried samples were then placed in a JEOL JFD-320 cold dryer, and once the temperature reached room temperature, they were coated with a conductive paste using a JEOL JFCC-160 ion sputterer. The samples were then observed and photographed using a HITACHI Regulus 8100 scanning electron microscope.

Transmission electron microscope

Logarithmically growing GBC-X1 cells (P33) were collected by centrifugation. The cells were fixed in a fixative solution of 2% Paraformaldehyde − 2.5% Glutaraldehyde, followed by flushing with 0.1 mol/L dimethyl Sodium arsenate buffer (pH = 7.4). Subsequently, the cells were further fixed with 1% osmium tetroxide, washed with double-distilled water, dehydrated with a gradient of ethanol to propylene oxide, and embedded in SPI812 resin. Semi-thin sections of 1 µM using the Leica EMUC7 slicing mechanism. After observation and positioning under a light microscope with azure methylene blue staining, 60 nm ultra-thin sections were prepared using Leica EMUC7 slicing mechanism. These sections were stained with uranyl acetate and lead citrate and subjected to observation and image analysis using HITACHI H-7650 Transmission electron microscopy.

Drug sensitivity experiment

Logarithmically growing GBC-X1 cells (P45) were trypsinized and prepared as a single-cell suspension. A total of 10,000 cells per 100 µl were inoculated into each well of a 96-well plate, with six wells repeated in each group. After cells adhered to the wall, the experimental group was treated with different concentrations of anti-tumor drugs, while the control group was treated with corresponding drug solubilizers. After 72 h of drug action, the complete medium was replaced with 100 µl serum-free medium containing 10% (v/v) CCK8. After a 2-hour incubation, the optical density (OD) value at 450 nm was measured.

Transwell chamber migration assay

Cultivated cells in serum-free medium for 1 day in advance. GBC-X1 cells (P40) were collected after trypsin digestion, adjusted the cell concentration to 7.5 × 105/mL, and added 200ul of cell suspension to the upper chamber of Transwell. Added 700 ul of complete culture medium containing 15% FBS to the lower chamber of Transwell. Cultivated them for 48 h. Discarded the culture medium from the upper and lower chambers, gently washed the upper and lower chambers 1–2 times with 1 ml PBS, added 1 ml of 4% paraformaldehyde, fixed for 15 min, and then discarded. Added 1.5 ml of 0.1% crystal violet staining solution to the Transwell chamber, stained for 30 min, and discarded. Washed the Transwell upper chamber three times in ultrapure water, washed the bottom of the upper chamber membrane with a wet cotton ball, and then washed again once. Placed the Transwell upper chamber on a glass slide and observed and taked photos under a microscope.

Transwell chamber invasion assay

Cultivated cells (P40) in serum-free medium for 1 day. Diluted the Matrigel with serum-free medium at a ratio of 1:8 under 4℃ conditions. Took 50 ul of matrigel and added it to the Transwell upper chamber, evenly covering the polycarbonate film. Placed the Transwell upper chamber in a 37℃ cell culture incubator for 30 min, then discarded any excess liquid in the upper chamber. Collected the cells with trypsin, and adjusted the cell concentration to 7.5 × 105/mL, and added 200ul of cell suspension to the upper chamber of Transwell. Added 700 ul of complete culture medium containing 15% FBS to the lower chamber of Transwell. Cultivated them for 48 h. Discarded the culture medium from the upper and lower chambers, gently washed the upper and lower chambers 1–2 times with 1 ml PBS, added 1 ml of 4% paraformaldehyde, fixed for 15 min, and then discarded. Added 1.5 ml of 0.1% crystal violet staining solution to the Transwell chamber, stained for 30 min, and discarded. Washed the Transwell upper chamber three times in ultrapure water, washed the bottom of the upper chamber membrane with a wet cotton ball. Placed the Transwell upper chamber on a glass slide and observed and took photos under a microscope.

Xenograft formation experiment

Logarithmically growing cells (P40 and P45) were trypsinized and adjusted to a cell density of 1 × 107/ml. A total of 0.1 ml of cell suspension was inoculated on the right shoulder of five NXG mice. Tumor growth of the nude mice was observed and recorded the next day. After 4 weeks, the mice were euthanized, and the xenograft growth was observed upon dissection.

Immunohistochemical staining

Cells from the 42nd passage were digested and inoculated onto sterile slides for growth. After 48 h, the slides were washed with PBS, fixed with 4% paraformaldehyde for 15 min, air-dried, and treated with 0.5% Triton X-100 for 20 min. Paraffin sections of xenograft and primary tumors were prepared and baked overnight at 60 ℃. Dewaxing, gradient alcohol hydration, and antigen retrieval were performed using Dako’s Autostainer Link 48 instrument. The activity of peroxidase was blocked by incubating the slides with 3% hydrogen peroxide solution at 37 °C for 15 min. Then, 100 µL of normal goat serum was added dropwise and sealed at 37 ℃ for 15 min. The primary antibodies (CK7(catalog no. kit-0021, MXB, China), CK19(catalog no.kit-0030, MXB, China), Ki67(catalog no.RMA-0731, MXB, China), E-cadherin(catalog no.MAB-0738, MXB, China), Vimentin(catalog no. MAB-0735, MXB, China), MMP-2(catalog no. GB114959-50, Servicebio, China), CD44(catalog no. GB113500-50, Servicebio, China), SOX2(catalog no. GB11249-50, Servicebio, China), TP53(catalog no. GB111740-50, Servicebio, China) ) were incubated at 37 °C for 1 h. Color development was performed using the DAB staining solution kit (Dako), followed by rinsing with running water for 5 min. The slides were restrained with hematoxylin, dehydrated, and made transparent in xylene. Finally, the slides were sealed with neutral resin and observed under a microscope.

Statistical analysis

All statistical analyses were conducted using SPSS 26.0 software. The data were presented as mean ± SD. Student’s t-tests and ANOVA were used for group comparisons. A P-value of < 0.05 was considered statistically significant.

Results

Establishment of GBC-X1 Cell line

A novel gallbladder cancer cell line, designated as GBC-X1, was successfully established through primary culture and subsequent subculture of primary tumor tissue obtained from a gallbladder cancer patient. Under the light microscope, GBC-X1 cells exhibited typical adherence to culture surface and displayed characteristic epithelial cell morphology. The cells are primarily polygonal, with prominent nuclei and nucleoli. The presence of multinucleated cells and megakaryocytes, along with the loss of contact inhibition, was observed (Fig. 1D). The cell line maintained stable morphology and remained unchanged after repeated freezing and revival. The postoperative pathological diagnosis of the patient’s primary tumor confirmed moderately to poorly differentiated GBC. The tumor cells displayed irregular arrangements in glandular, tubular, cord-like, and nest-like patterns (Fig. 1E). H&E staining revealed varying shapes of GBC-X1 cells, primarily short fusiform, characterized by enlarged nuclei, prominent nucleoli, limited cytoplasm, and the presence of multinucleated and megakaryocytic cells, indicating typical features of malignant tumor cells (Fig. 1F).

Cell growth curve

GBC-X1 cells exhibited rapid proliferation with a short doubling time. The cells demonstrated consistent growth in RPMI-1640 culture medium supplemented with 10% fetal bovine serum. Using the CCK8 method, the population doubling time of GBC-X1 was determined to be 32 h (Fig. 2A).

Fig. 2 Characterization of GBC-X1. A: Growth curve of GBC-X1 cells. B: Karyotype analysis results of GBC-X1. The representative karyotypes of 98, XXXX del (4) p (12) del (5) p (21) der (10). C and D: Experimental results of tumor sphere formation of GBC-X1 ( scale bar = 100 μm).

Short tandem repeat analysis

The DNA typing results confirmed that both the submitted samples originated from the same individual, with a likelihood ratio (LR) of 5.2469 × 1026 (Table 2). This supports the notion that GBC-X1 shares the same origin as the primary tumor tissue and is free from contamination by existing cell lines. Thus, GBC-X1 represents a novel human gallbladder cancer cell line.Table 2 Short tandem repeat profile of GBC-X1 and tumor tissue

Loci	GBC-X1	Tumor tissue	Matching Probability	
Amelogenin	X	X	/	
D3S1358	16	16	0.0729	
D5S818	11   12	11   12	0.1518	
D2S1338	19   24	19   24	0.0314	
TPOX	8    11	8    11	0.2140	
CSF1PO	12   13	12   13	0.0863	
Penta D	9	9	0.0908	
Y- Indel	-	-	/	
TH01	8    9	8    9	0.0354	
vWA	14   16	14   16	0.0900	
D7S820	8    12	8    12	0.0533	
D21S11	30   31.2	30   31.2	0.0341	
Penta E	10   20	10   20	0.0040	
D10S1248	16   17/18	14   16/17	/	
D8S1179	13	13	0.0676	
D1S1656	17.3  18.3	17.3  18.3	0.0027	
D18S51	17    19	17    19	0.0020	
D12S391	19    20	19    20	0.0883	
D6S1043	16	13    16	/	
D19S433	14    15.2	14    15.2	0.0625	
D16S539	12    13	12    13	0.0608	
D13S317	9     12	9     12	0.0442	
FGA	21    25	21    25	0.0264	
LR			5.2469×1026	

Chromosome analysis

Karyotype analysis revealed that GBC-X1 cells predominantly exhibited a hypertetraploid karyotype, characterized by significant variations in chromosome number and morphology. The representative karyotype was identified as 98, XXXX del (4) p (12) del (5) p (21) der (10) (Fig. 2B).

Tumor sphere culture

When GBC-X1 cells were cultured on an ultra-low attachment culture plate, they demonstrated robust proliferation in RPMI-1640 medium without serum and additional growth factors, forming tumorspheres. Over time, the size of spheres gradually increased (Fig. 2C-D).

Scanning electron microscope and transmission electron microscope

Scanning electron microscopy revealed that GBC-X1 cells appeared predominantly spherical and polygonal in shape, displaying abundant Microvilli on the cell surface, uniform morphology, and the presence of filopodia (Fig. 3A-D). Transmission electron microscopy exhibited enlarged nuclei situated close to the nuclear membrane, evident nuclear membrane shrinkage, increased nucleoli, decreased organelle count, significant mitochondrial swelling and vacuolization, decreased mitochondrial cristae, and the presence of desmosome structures between cells (Fig. 4A-D).

Fig. 3 GBC-X1 ultrastructure under Scanning electron microscopy. A and B: GBC-X1 were mainly spherical and polygonal in shape (A, scale bar = 100 μm; B, scale bar = 30 μm). C and D: GBC-X1 cell surface is rich in Microvillus, with filamentous pseudopodia visible (arrow) ( scale bar = 5 μm).

Fig. 4 GBC-X1 ultrastructure under transmission electron microscopy. A: The nucleus of GBC-X1 is large and close to the nuclear membrane, with visible nuclear membrane shrinkage and an increase in the number of nucleoli (scale bar = 5 μm); B-D: The number of Organelle decreased, mitochondria swelled significantly (arrow), vacuolized, cristae decreased significantly, and desmosome structure was seen between cells (arrow) (scale bar = 1 μm).

Drug sensitivity experiment

Gemcitabine, paclitaxel, 5-FU, and oxaliplatin are commonly used chemotherapy drugs for gallbladder cancer. Our drug sensitivity experiment demonstrated that GBC-X1 cells exhibited resistance to oxaliplatin (IC50 = 10.65 µmol/L), while being sensitive to fluorouracil (IC50 = 0.50 µmol/L), gemcitabine (IC50 = 0.0035 µmol/L), and paclitaxel (IC50 = 0.55 µg/mL) (Fig. 5A-D).

Fig. 5 Cell viability of GBC-X1 cells after 72 h of exposure to anticancer drugs. GBC-X1 is resistant to oxaliplatin (A) and sensitive to fluorouracil (B), gemcitabine (C), and paclitaxel (D).

Migration and invasion assay

In the migration assay, when GBC-X1 cells were seeded into the Transwell chamber for 24 h, the number of migrating cells was 9.33 ± 0.47(Fig. 6A), and after 48 h, the number of migrating cells was 195.67 ± 2.49(Fig. 6B); In the invasion assay, when cells were seeded into the Transwell chamber for 24 h, the number of transmembrane cells was 3.33 ± 0.47(Fig. 6C), while after 48 h, the number of transmembrane cells was 186 ± 4.90 (Fig. 6D).

Fig. 6 Migration and invasion assay of GBC-X1 cell line. A and B: As time increases, the number of migrating cells of GBC-X1 significantly increases ( scale bar = 200 μm ). C and D: As time increases, the number of transmembrane cells significantly increases, but compared to migratory cells, the number of cells is less ( scale bar = 200 μm ).

Xenograft formation experiment

Assess the in vivo xenograft formation capability of GBC-X1, 1 × 106 cells were subcutaneously inoculated into five NXG mice(Fig. 7A-B). The results confirmed that GBC-X1 can form xenografts after subcutaneous inoculation in NXG mice, with a xenograft formation rate of 80%(Fig. 7C-D). No metastatic lesions were observed in the liver and lungs upon dissection of the mice (Fig. 7E-F). The xenograft sections stained with H&E exhibited irregular glandular-like structures formed by the cells, demonstrating moderate to low differentiation. The histological morphology of the xenograft closely resembled that of the primary tumor, with large, deeply stained nuclei and an increased number of mitotic figures (Fig. 7G). These findings suggest that GBC-X1 cells display vigorous proliferation, consistent with malignant tumor characteristics.

Fig. 7 Tumorigenicity of the GBC-X1 cell line in vivo. A-D: GBC-X1 could form transplanted tumors in NXG mice, with a tumor formation rate of 80%. E and F: No metastatic lesions were found in the liver and lungs of the dissected mice after 4 weeks. G: The xenograft exhibited irregular glandular-like structures formed by the cells, demonstrating moderate to low differentiation (scale bar = 50 μm).

Fig. 8 Immunohistochemical staining of GBC-X1 cells, xenograft, and primary tumor. GBC-X1 (A1), xenograft (B1), and primary tumor (C1) show positive expression of CK7. GBC-X1 (A2), xenograft (B2), and primary tumor (C2) show positive expression of CK19. GBC-X1 (A3), xenograft (B3), and primary tumor (C3) exhibit positive expression of E-cadherin. GBC-X1 (A4), xenograft (B4), and primary tumor (C4) weakly express Vimentin. The positive rate of Ki67 is 35% in GBC-X1 (A5), xenograft (B5), and primary tumor (C5). GBC-X1 (A6), xenograft (B6), and primary tumor (C6) exhibit positive expression of MMP-2. GBC-X1 (A7), xenograft (B7), and primary tumor (C7) exhibit positive expression of CD44. GBC-X1 (A8), xenograft (B8), and primary tumor (C8) exhibit positive expression of SOX2. GBC-X1 (A9), xenograft (B9), and primary tumor (C9) exhibit positive expression of TP53(scale bar = 50 μm). .

Immunohistochemical staining

Immunohistochemical staining demonstrated positive expression of GBC-X1 cells and xenograft showed elevated expression levels of CK7 (Fig. 8A1-B1), CK19 (Fig. 8A2-B2), E-cadherin (Fig. 8A3-B3),and weakly positive expression of Vimentin(Fig. 8A4-B4),. The primary tumor also exhibited positive expression of CK7(Fig. 8C1), CK19(Fig. 8C2), E-cadherin(Fig. 8C3), Vimentin(Fig. 8C4), confirming their shared origin. The Ki67 labeling index was determined to be 35%, indicating a high proliferation rate(Fig. 8A5-C5). Immunohistochemistry exhibited positive expression of MMP-2 (Fig. 8A6-C6), CD44 (Fig. 8A7-C7), SOX2(Fig. 8A8-C8) and TP53(Fig. 8A9-C9) in cell lines, xenograft and primary tumour.

Discussion

Gallbladder cancer patients are often diagnosed in the middle to late stages of the disease due to the lack of obvious early symptoms, resulting in a low proportion of surgeries and poor prognosis. Understanding the underlying mechanisms of GBC occurrence and development is crucial to explore effective treatment methods and improving patient survival rates4,9–11. However, progress in gallbladder cancer pathogenesis and drug development has been greatly hindered by the limited availability of gallbladder cancer cell lines.

In this study, we successfully established a new gallbladder cancer cell line, designated as GBC-X1, through primary culture and subculture of primary tumor tissue obtained from gallbladder cancer patients. GBC-X1 has been continuously cultivated for over a year and has undergone stable passaging for more than 60 generations. Morphologically, GBC-X1 cells display typical adherence to the culture surface, resembling epithelial cells with short spindle shapes, large nuclei, and prominent nucleoli. Multinucleated cells and megakaryocytes are also observed. STR analysis confirmed the high consistency of GBC-X1 with the patient’s primary tumor, ensuring that the cell line was free from contamination by other cell lines or microorganisms. The observed Ki67 expression level of 35% in GBC-X1 suggests active proliferation of GBC-X1, which is consistent with the population doubling time of 32 h. GBC-X1 was compared with different gallbladder cancer cell line developed previously in Table 3.Table 3 Comparison of GBC-X1 with other cell lines

Cell line	GBC-X1	G−415	GBC-SD	NOZ	TYGBK−1	SNU−308	Mz-ChA−1	Mz-ChA−2	
Primary culture (yrs)	2022	1978	1999	--	2008	--	--	--	
Age at sampling (yrs)	72	68	61	48	67	--	55	63	
Doubling time (hrs)	32	48	21.4	48	48	48	72–120	48–60	
Derived from site	Gallbladder	Ascites	Gallbladder	Ascites	Lymph node	Gallbladder	Abdominal wall metastasis	liver metastases	
Sex of cell	Female	Male	Male	Female	Female	--	Female	Female	
Population	Chinese	Japanese	Chinese	Japanese	Japanese	Korean	German	German	
Xenograft formation	Yes	Yes	Yes	Yes	Yes	--	Yes	Yes	
Sensitivity to gemcitabine	Yes	No	Yes	Yes	Yes	--	--	--	
Karyotype	Hypertetraploid	Hypotriploid	Sub-tetraploid	--	Hypotriploid	--	Sub-tetraploid	Sub-tetraploid	
Degree of

differentiation

	Moderately to poorly	Undifferentiated	--	Moderately	Moderately	Moderately	Well	Poorly	
--, Unavailable.

Tumor spheroids have been widely studied since their discovery by Sutherland and colleagues in the early 1970s19. They are formed by the spontaneous aggregation of cells, mediated by cell surface integrins binding to the extracellular matrix (ECM)20. Various factors, such as nutrients, oxygen, and growth factors, influence this process21. Notably, tumor-derived spheroids are enriched with tumor stem cells and are commonly used for chemotherapy drug screening22,23. In our study, GBC-X1 demonstrated the efficient formation of tumor spheroids in a serum-free medium without the addition of growth factors, highlighting its strong stem cell characteristics.

The expression of CK7 and CK19 serves as a marker for bile duct differentiation, as normal bile duct epithelial cells and the majority of bile duct cancers express these proteins. Therefore, positive expression of CK7 and CK19 confirms the biliary epithelium origin24–26. Epithelial-mesenchymal transition (EMT) is a cellular process associated with various tumor functions, including tumor initiation, malignant progression, tumor stem cell properties, tumor cell migration, blood invasion, metastasis, and chemotherapy resistance. EMT is characterized by the loss of the epithelial marker E-cadherin and the acquisition of the mesenchymal marker Vimentin expression27–29. In our study, GBC-X1 cells exhibited positive expression of both E-cadherin and Vimentin, indicating their EMT characteristics consistent with malignant tumors.

Aneuploidy are prominent features of human tumors: approximately 90% of solid tumors and 70% of hematopoietic malignancies display a certain degree of aneuploidy30–32. The presence of aneuploid karyotypes in tumor cells is closely associated with poor patient prognosis33,34. Triploid karyotypes may be linked to intrinsic drug resistance whereas karyotypes exceeding tetraploidy could be associated with acquired drug resistance35. The incidence of hypertetraploid in women with breast cancer was 5.9%, while in men it was 16%36,37 Bjelkenkrantz et al. found that hypertetraploid is associated with a high recurrence rate and disease progression of tumors38. GBC-X1 cells predominantly exhibit a hypertetraploid karyotype, represented by 98, XXXX del (4) p (12) del (5) p (21) der (10). These cells demonstrate resistance to oxaliplatin, but sensitivity to gemcitabine, fluorouracil, and paclitaxel. Thus, GBC-X1 serves as a valuable model for investigating the mechanisms underlying karyotype-related drug resistance.

The mouse xenograft model plays a crucial role in advancing our understanding of human tumor biology, enabling the study of carcinogenesis, tumor progression, and evaluation of therapeutic compound efficacy and toxicity39,40. However, not all cell lines are capable of forming xenografts when inoculated into nude mice41,42. In our study, GBC-X1 cells were successfully inoculated into NXG mice, resulting in the formation of subcutaneous transplant tumors at a rate of approximately 50%. This observation may be attributed to residual immunity in mice. Pathological examination confirmed that the morphology of GBC-X1 xenografts closely resembled that of the primary tumor, further validating GBC-X1 as a viable animal experimental model.

Oxaliplatin targets DNA as the target site, and platinum atoms form cross junctions with DNA to counteract its replication and transcription43. Gemcitabine is a pyrimidine based anti-tumor drug, and its main metabolite is incorporated into DNA in cells, mainly acting in the G1/S phase44. Fluorouracil is a pyrimidine analogue that belongs to the category of anti metabolic drugs45. Paclitaxel can cause the dynamic balance between microtubule proteins and the dimer of microtubule proteins, inducing and promoting microtubule protein aggregation, microtubule assembly, and preventing depolymerization, thereby stabilizing microtubules and inhibiting cancer cell mitosis and triggering cell apoptosis, effectively preventing cancer cell proliferation and playing an anticancer role46.

The doubling time of GBC-X1 cells in this study was 32 h, indicating that GBC-X1 is a highly proliferative cell line. Therefore, antiproliferative drugs such as gemcitabine, paclitaxel, and fluorouracil can inhibit cell proliferation; Cell proliferation is vigorous, and the intracellular DNA excision repair system may be overexpressed, leading to the occurrence of oxaliplatin resistance47. In the later stage, we will further clarify the mechanism of GBC-X1 resistance through molecular detection.

Of course, this study only identified and analyzed the establishment and biological characteristics of a new gallbladder cancer cell line GBC-X1, which may limit the universal application of this study in a wider population of GBC patients. The subsequent establishment of more new gallbladder cancer cell lines and their sequencing analysis may deepen our understanding of the occurrence, development and the drug resistance mechanism of gallbladder cancer.

In conclusion, we have presented a novel human gallbladder cancer cell line, GBC-X1, derived from a Chinese female patient. This new cell line serves as a valuable experimental model for advancing basic research and facilitating the development of new therapeutic approaches for gallbladder cancer.

Acknowledgements

We would like to thank Bullet Edits (http://www.bulletedits.cn) for English language editing of the manuscript.

Author contributions

C.P.C, H.T, X.M , T.T.C and Y.H.S analyzed and interpreted the results of the detection of this novel cell line, and wrote a part of the manuscript. H.X, L.L, L.M and B.Z performed identification of the cell line, and were major contributors in writing the manuscript. Z.F.W, W.L and H.Z were responsible for specimen collection. W.C.Z wrote part of the manuscript and modified the images and were involved in data processing. C.P.C, H.T, X.M, T.T.C and H.X performed the cell culture. C.P.C, H.T, X.M, Y.H.S, L.L produced the pathological sections. Z.F.W, W.L and H.Z organized the data for all the experiments. W.C.Z and H.X conceived and designed and supervised the study. All authors read and approved the final manuscript.

Funding

This work was supported by grants from National Natural Science Foundation of China(Grants 82260555 and 82360510), Natural Science Foundation of Gansu Province (Grants 22JR11RA022, 22JR5RA901, 23JRRA0929 and 23JRRA1601), Lanzhou Science and Technology Plan Project (Grants 2022-3-45 and 2023-2-38), Intra-Hospital Fund of the First Hospital of Lanzhou University (Grant ldyyyn2022-12 ), Chengguan District Science and Technology Plan (Grant 2023SHFZ0018).

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Consent for publication

We have obtained consents to publish this paper from all the participants of this study.

Competing interests

The authors declare no competing interests.

Ethical approval

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Lanzhou University Second Hospital (2023 A-381). Informed consent was obtained from the patient. The animal procedures were approved by the Medical Animal Experiment Ethics Committee of Lanzhou University Second Hospital (D2023-318).

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Changpeng Chai, Huan Tang, Xin Miao and Tingting Chen contributed equally to this work.
==== Refs
References

1. Siegel, R. L., Miller, K. D., Jemal, A. & Cancer statistics CA Cancer J Clin. 70, 7–30. (2020). 10.3322/caac.21590 (2020).
2. Menon, G. & Babiker, H. M. Gallbladder carcinoma. in StatPearls (StatPearls Publishing, Treasure Island, FL, 2024).
3. Sung H Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338
Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249. 10.3322/caac.21660 (2021).33538338 10.3322/caac.21660
4. Song, X. et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 5, 230. (2020). 10.1038/s41392-020-00324-2 (2020).
5. Miranda-Filho A Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends Int. J. Cancer 2020 147 978 989 10.1002/ijc.32863 31922259
Miranda-Filho, A. et al. Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends. Int. J. Cancer. 147, 978–989. 10.1002/ijc.32863 (2020).31922259 10.1002/ijc.32863
6. Schmidt MA Marcano-Bonilla L Roberts LR Gallbladder cancer: epidemiology and genetic risk associations Chin. Clin. Oncol. 2019 8 31 10.21037/cco.2019.08.13 31484487
Schmidt, M. A., Marcano-Bonilla, L. & Roberts, L. R. Gallbladder cancer: epidemiology and genetic risk associations. Chin. Clin. Oncol. 8, 31. 10.21037/cco.2019.08.13 (2019).31484487 10.21037/cco.2019.08.13
7. Tuo, J. Y. et al. Report of incidence and mortality of gallbladder cancer in China, Zhonghua zhong liu za zhi [Chinese journal of oncology], 40, 894–899. (2014). 10.3760/cma.j.issn.0253-3766.2018.12.004 (2018).
8. Li YS Li ML Liu YB Current status and future prospects of basic research on gallbladder carcinoma Chin. J. Practical Surg. 2021 41 4
Li, Y. S., Li, M. L. & Liu, Y. B. Current status and future prospects of basic research on gallbladder carcinoma. Chin. J. Practical Surg. 41, 4 (2021).
9. Lamarca A Current standards and future perspectives in adjuvant treatment for biliary tract cancers Cancer Treat. Rev. 2020 84 101936 10.1016/j.ctrv.2019.101936 31986437
Lamarca, A. et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat. Rev. 84, 101936. 10.1016/j.ctrv.2019.101936 (2020).31986437 10.1016/j.ctrv.2019.101936
10. Yuan B Patient-derived organoids for personalized gallbladder cancer modelling and drug screening Clin. Transl Med. 2022 12 e678 10.1002/ctm2.678 35075805
Yuan, B. et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin. Transl Med. 12, e678. 10.1002/ctm2.678 (2022).35075805 10.1002/ctm2.678
11. Xing J Application and progress of cultured models of Gallbladder Carcinoma J. Clin. Transl Hepatol. 2023 11 695 704 10.14218/JCTH.2022.00351 36969882
Xing, J. et al. Application and progress of cultured models of Gallbladder Carcinoma. J. Clin. Transl Hepatol. 11, 695–704. 10.14218/JCTH.2022.00351 (2023).36969882 10.14218/JCTH.2022.00351
12. Koyama S Establishment of a cell line (G-415) from a human gallbladder carcinoma Gan 1980 71 574 575 7429092
Koyama, S. et al. Establishment of a cell line (G-415) from a human gallbladder carcinoma. Gan. 71, 574–575 (1980).7429092
13. Mirabelli P Coppola L Salvatore M Cancer Cell lines are useful Model systems for Medical Research Cancers (Basel) 2019 11 1098 10.3390/cancers11081098 31374935
Mirabelli, P., Coppola, L. & Salvatore, M. Cancer Cell lines are useful Model systems for Medical Research. Cancers (Basel). 11, 1098. 10.3390/cancers11081098 (2019).31374935 10.3390/cancers11081098
14. Guo L GBCdb: RNA expression landscapes and ncRNA-mRNA interactions in gallbladder carcinoma BMC Bioinform. 2023 24 12 10.1186/s12859-023-05133-2
Guo, L. et al. GBCdb: RNA expression landscapes and ncRNA-mRNA interactions in gallbladder carcinoma. BMC Bioinform. 24, 12. 10.1186/s12859-023-05133-2 (2023).10.1186/s12859-023-05133-2
15. Lin SJ Signatures of tumour immunity distinguish Asian and non-asian gastric adenocarcinomas Gut 2015 64 1721 1731 10.1136/gutjnl-2014-308252 25385008
Lin, S. J. et al. Signatures of tumour immunity distinguish Asian and non-asian gastric adenocarcinomas. Gut. 64, 1721–1731. 10.1136/gutjnl-2014-308252 (2015).25385008 10.1136/gutjnl-2014-308252
16. Nassour I Racial and ethnic disparities in a national cohort of ampullary cancer patients J. Surg. Oncol. 2018 117 220 227 10.1002/jso.24835 28968918
Nassour, I. et al. Racial and ethnic disparities in a national cohort of ampullary cancer patients. J. Surg. Oncol. 117, 220–227. 10.1002/jso.24835 (2018).28968918 10.1002/jso.24835
17. Hattori E Oyama R Kondo T Systematic review of the current status of human sarcoma cell lines Cells 2019 8 157 10.3390/cells8020157 30781855
Hattori, E., Oyama, R. & Kondo, T. Systematic review of the current status of human sarcoma cell lines. Cells. 8, 157. 10.3390/cells8020157 (2019).30781855 10.3390/cells8020157
18. Xu H Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1 World J. Gastroenterol. 2023 29 2642 2656 10.3748/wjg.v29.i17.2642 37213400
Xu, H. et al. Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1. World J. Gastroenterol. 29, 2642–2656. 10.3748/wjg.v29.i17.2642 (2023).37213400 10.3748/wjg.v29.i17.2642
19. Sutherland RM McCredie JA Inch WR Growth of multicell spheroids in tissue culture as a model of nodular carcinomas J. Natl. Cancer Inst. 1971 46 113 120 5101993
Sutherland, R. M., McCredie, J. A. & Inch, W. R. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst. 46, 113–120 (1971).5101993
20. Steinberg MS Differential adhesion in morphogenesis: a modern view Curr. Opin. Genet. Dev. 2007 17 281 286 10.1016/j.gde.2007.05.002 17624758
Steinberg, M. S. Differential adhesion in morphogenesis: a modern view. Curr. Opin. Genet. Dev. 17, 281–286. 10.1016/j.gde.2007.05.002 (2007).17624758 10.1016/j.gde.2007.05.002
21. Bates RC Edwards NS Yates JD Spheroids and cell survival Crit. Rev. Oncol. Hematol. 2000 36 61 74 10.1016/s1040-8428(00)00077-9 11033297
Bates, R. C., Edwards, N. S. & Yates, J. D. Spheroids and cell survival. Crit. Rev. Oncol. Hematol. 36, 61–74. 10.1016/s1040-8428(00)00077-9 (2000).11033297 10.1016/s1040-8428(00)00077-9
22. Gunti S Hoke ATK Vu KP London NR Jr Organoid and Spheroid Tumor models: techniques and applications Cancers 2021 13 874 10.3390/cancers13040874 33669619
Gunti, S., Hoke, A. T. K., Vu, K. P. & London, N. R. Jr Organoid and Spheroid Tumor models: techniques and applications. Cancers. 13, 874. 10.3390/cancers13040874 (2021).33669619 10.3390/cancers13040874
23. Nath S Devi GR Three-dimensional culture systems in cancer research: focus on tumor spheroid model Pharmacol. Ther. 2016 163 94 108 10.1016/j.pharmthera.2016.03.013 27063403
Nath, S. & Devi, G. R. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol. Ther. 163, 94–108. 10.1016/j.pharmthera.2016.03.013 (2016).27063403 10.1016/j.pharmthera.2016.03.013
24. Takahashi Y Application of immunohistochemistry in the pathological diagnosis of liver tumors Int. J. Mol. Sci. 2021 22 5780 10.3390/ijms22115780 34071338
Takahashi, Y. et al. Application of immunohistochemistry in the pathological diagnosis of liver tumors. Int. J. Mol. Sci. 22, 5780. 10.3390/ijms22115780 (2021).34071338 10.3390/ijms22115780
25. Uhlén M A human protein atlas for normal and cancer tissues based on antibody proteomics Mol. Cell. Proteom. 2005 4 1920 1932 10.1074/mcp.M500279-MCP200
Uhlén, M. et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteom. 4, 1920–1932. 10.1074/mcp.M500279-MCP200 (2005).10.1074/mcp.M500279-MCP200
26. Malaguarnera G Markers of bile duct tumors World J. Gastrointest. Oncol. 2011 3 49 59 10.4251/wjgo.v3.i4.49 21528090
Malaguarnera, G. et al. Markers of bile duct tumors. World J. Gastrointest. Oncol. 3, 49–59. 10.4251/wjgo.v3.i4.49 (2011).21528090 10.4251/wjgo.v3.i4.49
27. Nieto MA Huang RY Jackson RA Thiery JP EMT: 2016 Cell. 2016 166 21 45 10.1016/j.cell.2016.06.028 27368099
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016 Cell. 166, 21–45. 10.1016/j.cell.2016.06.028 (2016).27368099 10.1016/j.cell.2016.06.028
28. Pastushenko I Blanpain CEMT Transition States during Tumor Progression and Metastasis Trends Cell Biol. 2019 29 212 226 10.1016/j.tcb.2018.12.001 30594349
Pastushenko, I. & Blanpain, C. E. M. T. Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 29, 212–226. 10.1016/j.tcb.2018.12.001 (2019).30594349 10.1016/j.tcb.2018.12.001
29. Bakir B Chiarella AM Pitarresi JR Rustgi AK EMT MET, plasticity, and Tumor Metastasis Trends Cell. Biol. 2020 30 764 776 10.1016/j.tcb.2020.07.003 32800658
Bakir, B., Chiarella, A. M., Pitarresi, J. R., Rustgi, A. K. & EMT MET, plasticity, and Tumor Metastasis. Trends Cell. Biol. 30, 764–776. 10.1016/j.tcb.2020.07.003 (2020).32800658 10.1016/j.tcb.2020.07.003
30. Weaver BA Cleveland DW Does aneuploidy cause cancer? Curr. Opin. Cell. Biol. 2006 18 658 667 10.1016/j.ceb.2006.10.002 17046232
Weaver, B. A. & Cleveland, D. W. Does aneuploidy cause cancer? Curr. Opin. Cell. Biol. 18, 658–667. 10.1016/j.ceb.2006.10.002 (2006).17046232 10.1016/j.ceb.2006.10.002
31. Xiao R Aneuploid embryonic stem cells drive teratoma metastasis Nat. Commun. 2024 15 1087 10.1038/s41467-024-45265-4 38316790
Xiao, R. et al. Aneuploid embryonic stem cells drive teratoma metastasis. Nat. Commun. 15, 1087. 10.1038/s41467-024-45265-4 (2024).38316790 10.1038/s41467-024-45265-4
32. Taylor AM Genomic and functional approaches to understanding Cancer Aneuploidy Cancer Cell. 2018 33 676 689e3 10.1016/j.ccell.2018.03.007 29622463
Taylor, A. M. et al. Genomic and functional approaches to understanding Cancer Aneuploidy. Cancer Cell. 33, 676–689e3. 10.1016/j.ccell.2018.03.007 (2018).29622463 10.1016/j.ccell.2018.03.007
33. Chen Y Yang Z Wang Y Wang J Wang C Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer BMC cancer 2019 19 651 10.1186/s12885-019-5850-7 31269908
Chen, Y., Yang, Z., Wang, Y., Wang, J. & Wang, C. Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer. BMC cancer. 19, 651. 10.1186/s12885-019-5850-7 (2019).31269908 10.1186/s12885-019-5850-7
34. Wang Y Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer J. Cancer Res. Clin. Oncol. 2019 145 2911 2920 10.1007/s00432-019-03040-9 31646374
Wang, Y. et al. Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer. J. Cancer Res. Clin. Oncol. 145, 2911–2920. 10.1007/s00432-019-03040-9 (2019).31646374 10.1007/s00432-019-03040-9
35. Huang M Aneuploid Circulating Tumor Cells as a predictor of response to Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer Int. J. Gen. Med. 2021 14 6609 6620 10.2147/IJGM.S330361 34703281
Huang, M. et al. Aneuploid Circulating Tumor Cells as a predictor of response to Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer. Int. J. Gen. Med. 14, 6609–6620. 10.2147/IJGM.S330361 (2021).34703281 10.2147/IJGM.S330361
36. Pinto AE André S Nogueira M Mendonça E Soares J Flow cytometric DNA hypertetraploidy is associated with unfavourable prognostic features in breast cancer J. Clin. Pathol. 1997 50 591 595 10.1136/jcp.50.7.591 9306941
Pinto, A. E., André, S., Nogueira, M., Mendonça, E. & Soares, J. Flow cytometric DNA hypertetraploidy is associated with unfavourable prognostic features in breast cancer. J. Clin. Pathol. 50, 591–595. 10.1136/jcp.50.7.591 (1997).9306941 10.1136/jcp.50.7.591
37. Bezić J Flow cytometric DNA hypertetraploidy tends to be more frequent in male than in female breast cancers Virchows Arch. 2015 466 185 189 10.1007/s00428-014-1694-3 25471639
Bezić, J. et al. Flow cytometric DNA hypertetraploidy tends to be more frequent in male than in female breast cancers. Virchows Arch. 466, 185–189. 10.1007/s00428-014-1694-3 (2015).25471639 10.1007/s00428-014-1694-3
38. Bjelkenkrantz K Lundgren J Olofsson J Single-cell DNA measurement in hyperplastic, dysplastic and carcinomatous laryngeal epithelia, with special reference to the occurrence of hypertetraploid cell nuclei Anal. Quant. Cytol. 1983 5 184 188 6651017
Bjelkenkrantz, K., Lundgren, J. & Olofsson, J. Single-cell DNA measurement in hyperplastic, dysplastic and carcinomatous laryngeal epithelia, with special reference to the occurrence of hypertetraploid cell nuclei. Anal. Quant. Cytol. 5, 184–188 (1983).6651017
39. Chuprin J Humanized mouse models for immuno-oncology research Nat. Rev. Clin. Oncol. 2023 20 192 206 10.1038/s41571-022-00721-2 36635480
Chuprin, J. et al. Humanized mouse models for immuno-oncology research. Nat. Rev. Clin. Oncol. 20, 192–206. 10.1038/s41571-022-00721-2 (2023).36635480 10.1038/s41571-022-00721-2
40. Massa, A. et al. Evolution of the Experimental Models of Cholangiocarcinoma. Cancers 12, 2308. (2020). 10.3390/cancers12082308
41. Shultz LD Human cancer growth and therapy in immunodeficient mouse models Cold Spring Harb Protoc. 2014 2014 7 694 708 10.1101/pdb.top073585 24987146
Shultz, L. D. et al. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014 (7), 694–708 (2014).24987146 10.1101/pdb.top073585
42. Shultz, L. D. et al. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 694–708. (2014). 10.1101/pdb.top073585 (2014).
43. Graham J Mushin M Kirkpatrick P Oxaliplatin Nat. Rev. Drug Discov 2004 3 11 12 10.1038/nrd1287 14756144
Graham, J., Mushin, M., Kirkpatrick, P. & Oxaliplatin Nat. Rev. Drug Discov 3, 11–12. 10.1038/nrd1287 (2004).14756144 10.1038/nrd1287
44. Pandit B Royzen M Recent development of Prodrugs of Gemcitabine Genes 2022 13 466 10.3390/genes13030466 35328020
Pandit, B. & Royzen, M. Recent development of Prodrugs of Gemcitabine. Genes. 13, 466. 10.3390/genes13030466 (2022).35328020 10.3390/genes13030466
45. Longley DB Harkin DP Johnston PG 5-fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 2003 3 330 338 10.1038/nrc1074 12724731
Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 3, 330–338. 10.1038/nrc1074 (2003).12724731 10.1038/nrc1074
46. Min L Strategies and lessons learned from total synthesis of Taxol Chem. Rev. 2023 123 4934 4971 10.1021/acs.chemrev.2c00763 36917457
Min, L. et al. Strategies and lessons learned from total synthesis of Taxol. Chem. Rev. 123, 4934–4971. 10.1021/acs.chemrev.2c00763 (2023).36917457 10.1021/acs.chemrev.2c00763
47. Cohen R Statuts MMR et BRAF dans les cancers colorectaux: intérêts pour la prise en charge thérapeutique? [DNA mismatch repair and BRAF status in colorectal cancer: interest for the therapeutic management?] Bull. Cancer 2015 102 S72 S81 10.1016/S0007-4551(15)31220-0 26118880
Cohen, R. et al. Statuts MMR et BRAF dans les cancers colorectaux: intérêts pour la prise en charge thérapeutique? [DNA mismatch repair and BRAF status in colorectal cancer: interest for the therapeutic management?]. Bull. Cancer. 102, S72–S81. 10.1016/S0007-4551(15)31220-0 (2015).26118880 10.1016/S0007-4551(15)31220-0
